Telehealth and weight-loss programs: 65 matched rules, 26 that block approval

• Regulatory status19
• Platform policy17
• Replaces care9
• State law7
• Absolute promises3
• Disease claims3
• Efficacy and proof3
• Offers and pricing3
• Outcome statistics1

Federal and general rules first, blocking before warning, citations checked against stored text before the rest. Rules with their own page link there.

1. CG-CSR-001 · Blocks approval · Citation checked against stored text

   Prescribing a controlled substance without a real evaluation, records or follow-up violates the Controlled Substances Act and DEA telemedicine rules.

   Source: 21 U.S.C. 829 and 841(h); 21 CFR 1306.04 (prescription issued for a legitimate medical purpose); 21 CFR 1306.05 (manner of issuance, so a prescription must carry the patient and practitioner details); FTC Act section 5

   Safer wording: Do not advertise controlled substances. A licensed clinician must decide whether to prescribe after a real evaluation.

   21 CFR 1306.04, 21 U.S.C. 829, 21 CFR 1306.05 · Needs counsel review

2. CG-DEA-003 · Blocks approval · Citation checked against stored text

   Offering to fill a prescription for a controlled substance based only on an online questionnaire is a listed example of an internet distribution violation.

   Source: 21 U.S.C. 841 subsection (h) lists offering to fill a controlled substance prescription based solely on a consumer's online medical questionnaire as an example of a violation

   Safer wording: Do not tie a controlled substance prescription to a questionnaire alone. Describe a live evaluation by a licensed practitioner who decides if a prescription is appropriate.

   21 U.S.C. 841 · Needs counsel review

3. CG-DIS-028 · Blocks approval · Citation checked against stored text

   Comparing a supplement to a GLP-1 prescription drug ("natural Mounjaro", "mimics Ozempic") claims drug-like effects on weight and blood sugar and implies the product does what an approved drug does.

   Source: FDCA 201(g)(1); 21 CFR 101.93(g); FTC Act section 5; FTC Health Products Compliance Guidance

   Safer wording: Do not name or compare to a prescription drug. Describe the ingredients.

   21 CFR 101.93(g) · Needs counsel review

4. CG-OIG-001 · Blocks approval · Citation checked against stored text

   Paying or rewarding anyone for referring patients or for each prescription can violate the federal anti-kickback statute, and paying influencers without disclosure violates endorsement rules.

   Source: federal anti-kickback statute, 42 U.S.C. 1320a-7b; OIG Special Fraud Alert on telemedicine arrangements; FTC Endorsement Guides, 16 CFR Part 255

   Safer wording: Remove payments tied to referrals or prescriptions. Pay marketers a fixed fee for services set in advance, and require clear disclosure of any paid endorsement.

   16 CFR Part 255, 42 U.S.C. 1320a-7b · Needs counsel review

5. CG-OIG-002 · Blocks approval · Citation checked against stored text

   Routinely waiving copays, paying premiums, billing one service as another, or offering free items to people on federal health programs can violate the anti-kickback statute and the False Claims Act.

   Source: federal anti-kickback statute, 42 U.S.C. 1320a-7b; OIG Special Fraud Alert on telemedicine arrangements; 42 CFR 422.2263

   Safer wording: Do not advertise copay waivers, premium payments or free items for Medicare and Medicaid patients, and bill every service accurately.

   42 CFR 422.2263, 42 U.S.C. 1320a-7b · Needs counsel review

6. CG-RAF-002 · Blocks approval · Citation checked against stored text

   Discounting and price-led promotion of prescription weight-loss treatment, such as sales events and rock-bottom prices, markets a prescription drug as a commodity and invites purchase without a clinical assessment.

   Source: 21 CFR 202.1 (prescription drug advertising); FDA warning letters to telehealth firms on compounded GLP-1 marketing; FTC Act section 5. UK ASA rulings are the origin of the pattern but UK law is out of scope.

   Safer wording: Do not use sales or lowest-price framing for prescription weight-loss treatment. State that treatment depends on a clinician assessment and describe fees plainly.

   21 CFR 202.1 · Needs counsel review

7. CG-RAF-003 · Blocks approval · Citation checked against stored text

   A first-person quantified weight-loss result presented as a testimonial implies typical results unless the ad states what consumers can generally expect.

   Source: FTC Endorsement Guides, 16 CFR 255.2(b) (results not typical must be backed by what is generally expected); FTC Act section 5. UK ASA rulings are the origin of the pattern but UK law is out of scope.

   Safer wording: Remove the specific result or state clearly the results typical users achieve, with substantiation, and disclose any material connection.

   16 CFR 255.2(b) · Needs counsel review

8. CG-RAF-008 · Blocks approval · Citation checked against stored text

   Detox and cleanse products that claim to remove toxins or heavy metals or produce weight loss make unsubstantiated claims. Medical detoxification for addiction is excluded.

   Source: FTC Act section 5 (FTC guidance on detox and cleanse claims); 21 CFR 101.93(g). UK ASA rulings are the origin of the pattern but UK law is out of scope.

   Safer wording: Remove claims that a product removes toxins or heavy metals or causes weight loss, or provide human studies of the finished product.

   21 CFR 101.93(g) · Needs counsel review

9. CG-REG-006 · Blocks approval · Citation checked against stored text

   Compounded drugs are not FDA approved and are not the same as, or generics of, the brand product. Telehealth sellers have received FDA warning letters for these claims.

   Source: FDCA 503A and 503B; FDA warning letters to telehealth firms on compounded GLP-1 marketing; FTC Act section 5

   Safer wording: Say the medication is compounded, that it is not FDA approved, and that a licensed clinician decides whether it is appropriate.

   FDCA 503A · Needs counsel review

10. CG-REG-007 · Blocks approval · Citation checked against stored text

    FDA has sent warning letters to telehealth and online sellers over marketing of compounded GLP-1 drugs and unapproved peptides. Compounded drugs are not FDA approved, and these products raise misbranding and unapproved-drug issues.

    Source: FDCA 503A and 503B; FDA warning letters to telehealth firms on compounded GLP-1 marketing

    Safer wording: If you offer a compounded drug, say it is compounded and not FDA approved, that a licensed clinician decides if it is appropriate, and have counsel review the claims and the pharmacy relationship.

    FDCA 503A · Needs counsel review

Sample wording we wrote to test these rules, run through the real engine at build time. The rule ids, reasons, sources and safer wording are the rule-set's own.

13 pages below meet the gate: at least 6 applicable rules and at least 3 that belong to that state or platform alone.